Efficacy News and Research

RSS
New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

New tools for neglected diseases: an interview with Dr. BT Slingsby, CEO, GHIT Fund

Researchers identify potential therapy for meibomian gland dysfunction

Researchers identify potential therapy for meibomian gland dysfunction

Preoperative antibiotics within two hours of cardiac surgery decrease risk of developing SSIs

Preoperative antibiotics within two hours of cardiac surgery decrease risk of developing SSIs

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

ANP reports positive interim results from ATL1103 Phase II clinical trial for acromegaly

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

Icahn School of Medicine receives $1.3M grant to build collaborative research infrastructure for stroke center

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

Real and sham weekly acupuncture treatments ease hot flashes of anticancer drug treatment

CUMC researchers clarify three fundamental issues about Alzheimer's disease

CUMC researchers clarify three fundamental issues about Alzheimer's disease

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Lilly, Boehringer Ingelheim announce FDA acceptance of NDA filing for new insulin glargine product

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Icahn School of Medicine at Mount Sinai joins NIH Stroke Trials Network

Icahn School of Medicine at Mount Sinai joins NIH Stroke Trials Network

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

Researchers reveal how metabolic system breaks down in obesity

Researchers reveal how metabolic system breaks down in obesity

Study: Standard treatment approaches yield modest to large improvement in TMD patients

Study: Standard treatment approaches yield modest to large improvement in TMD patients

New research assesses nanomedicine-based approaches for treating cancer

New research assesses nanomedicine-based approaches for treating cancer

BCG vaccine highly protective against pulmonary TB: Study

BCG vaccine highly protective against pulmonary TB: Study

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

BeiGene doses first patient in Phase 1 study of BGB-283

BeiGene doses first patient in Phase 1 study of BGB-283

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.